Placebo + Rufinamide
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Epilepsy
Conditions
Epilepsy
Trial Timeline
Feb 13, 2006 → May 20, 2009
NCT ID
NCT00334958About Placebo + Rufinamide
Placebo + Rufinamide is a phase 3 stage product being developed by Eisai for Epilepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT00334958. Target conditions include Epilepsy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00334958 | Phase 3 | Completed |
Competing Products
20 competing products in Epilepsy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| perampanel | Eisai | Phase 2 | 52 |
| Lacosamide | UCB | Phase 3 | 74 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| Zonegran | Eisai | Approved | 85 |
| perampanel + perampanel | Eisai | Phase 1 | 33 |
| Perampanel + Placebo | Eisai | Approved | 85 |
| perampanel | Eisai | Approved | 85 |
| E2007 + Placebo | Eisai | Phase 2 | 52 |
| E2007 (perampanel) + Placebo | Eisai | Phase 2 | 52 |
| Perampanel Oral Tablet | Eisai | Approved | 85 |
| perampanel | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Zonisamide + Carbamazepine | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Approved | 85 |
| Perampanel and Microgynon-30 + Perampanel and Microgynon-30 | Eisai | Phase 1 | 33 |
| Perampanel | Eisai | Phase 2 | 52 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| zonisamide low dose group + zonisamide high dose group | Eisai | Approved | 85 |
| E2007 + E2007 + Placebo | Eisai | Phase 2 | 52 |
| Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/day | Eisai | Approved | 85 |